Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sacituzumab govitecan - Immunomedics

X
Drug Profile

Sacituzumab govitecan - Immunomedics

Alternative Names: GS-0132; hRS7-SN38 antibody drug conjugate; IMMU-132; IMMU0132; Isactuzumab govitecan; Sacituzumab govitecan-hziy; TRODELVY; Trodelvy; TROP-2-SN-38

Latest Information Update: 06 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences; IBC Pharmaceuticals; Immunomedics; UNICANCER
  • Developer Clovis Oncology; Gilead Sciences; Immunomedics; M. D. Anderson Cancer Center; Merck Sharp & Dohme; Pfizer; UNICANCER; University of Wisconsin Comprehensive Cancer Center; Yale University
  • Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Indolizines; Monoclonal antibodies; Pyrans; Quinolines
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Breast cancer; Small cell lung cancer; Pancreatic cancer; Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Triple negative breast cancer; Urogenital cancer
  • Registered HER2 negative breast cancer
  • Phase III Non-small cell lung cancer; Solid tumours
  • Phase II Bladder cancer; Cervical cancer; Endometrial cancer; Prostate cancer
  • Phase I/II Cancer
  • No development reported Glioblastoma

Most Recent Events

  • 02 Jun 2024 Updated adverse events data from the phase III EVOKE-01 trial in Non-small cell lung cancer released by Gilead Sciences
  • 30 May 2024 Registered for Triple-negative-breast-cancer (Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease) in United Arab Emirates, Israel, Brazil (IV) prior to May 2024
  • 30 May 2024 Topline adverse events and efficacy data from phase-III TROPiCS-04 trial in Urogenital cancer released by Gilead
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top